Recently, the reporter learned from the China Society for Materials Research that the scale of China's new materials industry has grown at an average annual rate of 10%. In 14 years, the scale of the industry has exceeded 1.60 billion yuan, forming regional characteristics of the three new material industry clusters in the Yangtze River Delta, the Pearl River Delta and the Bohai Rim. . Among them, the biomedical materials industry is developing very rapidly, with an annual growth rate of 20%. In addition, it has been learned that the production and application technologies of graphene and nanomaterials independently developed by China have reached or are close to the international level. The development and production of biomedical materials in China has developed rapidly. The scale has begun to become an emerging industry, and the growth rate of total output value is much higher than the average growth rate of the national economy. At present, China's biomedical materials are mainly used as medical devices in clinical applications, and have become an important foundation of the entire medical device industry, and its products account for 40%-50% of the medical device market. At present, China has a huge demand for biomedical materials and products. China is entering an aging society. The number of elderly people over the age of 60 has reached 185 million, accounting for 13.7% of the national population. The old body is constantly causing pathological changes in the body tissues and organs, which requires timely treatment. Therefore, it is necessary to provide a large number of high-quality biological materials. Domestic development overview After nearly ten years of development, China's modern biomedical materials industry has taken shape and entered a stage of rapid development. It is understood that in February 2012, the state issued the "12th Five-Year Development Plan for New Materials Industry", and the special project of biomedical materials has become one of the new materials industries that are supported by development. During the "11th Five-Year Plan" period, China invested 400 million yuan in research on biomedical materials. During the "Twelfth Five-Year Plan" period, the figure increased to 510 million yuan. At the same time, the development of advanced medical equipment and biomedical materials have been incorporated into the national medium- and long-term scientific and technological development planning, and China has entered an important opportunity period for the development and application of biomedical materials. In 2013, China's medical device sales reached US$280 billion, with an annual growth rate of approximately 20%, of which biomedical materials sales were approximately US$120 billion, with an annual growth rate of more than 25%. However, although the basic research of biomedical materials in China has reached the international advanced level, imported products still occupy half of China's high-end market due to restrictions on professional and technical barriers and corporate capital investment. According to the data, the global biomedical materials market is highly concentrated, and multinational companies such as Johnson & Johnson and Medtronic control major markets. In recent years, multinational corporations have strengthened their domestic market position through mergers and acquisitions. Some domestic Hong Kong stocks and outstanding overseas listed companies and unlisted companies have been acquired by foreign companies. In the face of foreign investment, the domestic biomedical materials and their products industry want to break through, the process will be relatively difficult and long. Current status of foreign countries The biomedical materials and implanted device industry is the most cross-disciplinary and knowledge-intensive high-tech industry. Its development requires the support of upstream and downstream knowledge, technology and related environment. Most of them are concentrated in the economy, technology, talents or clinical resources. The region's high concentration is an important feature of the medical biomedical materials industry in developed countries. For example, the United States is concentrated in the technically rich Silicon Valley, the North Carolina Research Triangle Park, and the clinically resource-rich Minneapolis and Cleveland Medical Center; Germany is concentrated in the areas of Airland, Thuringia and other places in Bavaria. The biomedical materials industry is different from the home appliance or communication industry. The market capacity of a single product is not large, and the sales of most single products are less than US$10 billion. In order to enhance the competitiveness of the enterprise market, avoid risks, and develop and expand enterprises, foreign multinational companies have been producing from a single product, through internal technological innovation and mergers and acquisitions of other enterprises, continuously expanding and expanding product production lines to achieve multi-variety production. In order to open up the international market, multinational corporations have established subsidiaries and R&D centers in foreign countries through local technology and capital exports, and local production and R&D. At the same time, in order to adapt to the development of international trade, the International Organization for Standardization has continuously formulated and published international standards for biomedical materials and products. With the aging of the population, the increase of the trauma of middle and young people, the injection of high technology, and the concern of human beings for their own health with the development of the economy, the biomedical materials industry is developing at a high speed. From 2000 to 2010, the global market compound growth rate (CAGR) is as high as 22%. It is estimated that the world market will reach US$5 billion in 2015, while driving the related industries (excluding medical care) to increase production value by about 3 times. Conclusion The author believes that biomedical materials are expected to become a pillar industry in the world economy in the next 20 years. Biomedical materials that induce tissue or organ regeneration or reconstruction will become the mainstay of the biomedical materials industry. It is conservatively estimated that the two high-tech biomaterials market will grow to more than tens of billion yuan in the world around 2030. Correspondingly, it will also drive new indirect economic benefits for related industries. TCT HANGZHOU DIAN BIOTECHNOLOGY CO., LTD. , https://www.dianbiotech.com